Cabaletta Bio, Inc. (NASDAQ: CABA) reported a fourth‑quarter net loss of $36.2 million and a full‑year net loss of $167.9 million, while posting a GAAP earnings per share of –$0.40 for the quarter and –$0.45 for the year. The quarterly loss per share beat analyst expectations of –$0.47 by $0.07, a 15% improvement over the consensus estimate.
R&D expenses rose to $36.2 million in Q4 2025 from $25.5 million in Q4 2024, reflecting intensified investment in the RESET™ program and the expansion of the Cellares Cell Shuttle™ manufacturing partnership. General and administrative expenses were $6.4 million in Q4 2025, slightly lower than the $8.3 million recorded in Q4 2024, indicating modest cost discipline amid growing research outlays.
The earnings beat can be attributed to tighter-than‑expected operating costs and a lower-than‑anticipated loss margin. While R&D spending increased, the company managed to keep other operating expenses in check, resulting in a smaller loss per share than projected. This cost control, combined with the absence of large one‑time charges, allowed the company to outperform consensus forecasts.
On the clinical front, Cabaletta highlighted progress in its RESET™ program, noting the launch of a no‑preconditioning cohort and the continued development of the automated manufacturing platform with Cellares. The company expects data read‑outs from the RESET‑SLE and RESET‑PV trials in the first half of 2026, and it plans to file a Biologics License Application for rese‑cel in myositis in 2027 based on a 17‑patient registrational cohort.
Despite the positive earnings beat, the company reiterated a substantial doubt about its ability to continue as a going concern without additional funding. The increased R&D spend and ongoing cash burn underscore the need for future capital raises, while the clinical and manufacturing milestones provide a potential upside that could support future valuation and funding prospects. The company remains focused on achieving regulatory milestones and scaling its manufacturing capabilities to support eventual commercialization.
No new forward guidance was issued in the release; however, the company’s emphasis on upcoming data read‑outs and the planned BLA submission signals a continued commitment to advancing its pipeline and achieving regulatory milestones in the near term.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.